Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 26%
Hold 39%
Sell 4%
Strong Sell 0%

Bulls say

Biogen is expected to see significant revenue growth driven by its product portfolio, with combined sales projected to reach $689 million in 2025 and anticipated to increase at a mid- to high-teens percentage through 2028. The company's acquisition of APLS for $5.6 billion is poised to enhance its nephrology and immunology segments, further adding value to its shares and positioning it favorably for upcoming product developments. Additionally, Biogen's diverse range of offerings, including sales from Empaveli and the expected increase in revenues from Syfovre, contributes to a positive outlook, with forecasts suggesting peak revenues could approach $2.5 billion by 2038.

Bears say

Biogen faces significant challenges with its revenue-generating franchises, particularly with the anticipated decline in its multiple sclerosis franchise, which contributed 40% of total revenue in 2025. The company's newer products, including Spinraza and Leqembi, are at risk of lower-than-expected sales due to increased competition and potential reimbursement hurdles, while the commercial uptake of Syfovre is hampered by heavy reliance on free goods, gross-to-net pressures, and slow market adoption. Additionally, there are concerns regarding pipeline failures, management distractions, and unfavorable developments related to its collaboration agreements, all contributing to a negative outlook for Biogen's stock.

Biogen (BIIB) has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 26% recommend Buy, 39% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 23 analysts, Biogen (BIIB) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $207.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $207.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.